Stefan O Mueller
Overview
Explore the profile of Stefan O Mueller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
1067
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Essink B, Shapiro C, Isidro M, Bradley P, Pragalos A, Bloch M, et al.
Hum Vaccin Immunother
. 2024 Oct;
20(1):2408863.
PMID: 39422261
This phase 1, open-label, dose-escalation, multi-center study (NCT05477186) assessed the safety and immunogenicity of a booster dose of an mRNA COVID-19 vaccine (CV0501) encoding the SARS-CoV-2 Omicron BA.1 spike protein....
2.
Roth N, Gergen J, Kovacikova K, Mueller S, Ulrich L, Schon J, et al.
Vaccines (Basel)
. 2023 Feb;
11(2).
PMID: 36851196
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) Omicron and its subvariants (BA.2, BA.4, BA.5) represented the most commonly circulating variants of concern (VOC) in the coronavirus disease 2019 (COVID-19) pandemic in...
3.
Corleis B, Hoffmann D, Rauch S, Fricke C, Roth N, Gergen J, et al.
Nat Commun
. 2023 Feb;
14(1):816.
PMID: 36781853
Combining optimized spike (S) protein-encoding mRNA vaccines to target multiple SARS-CoV-2 variants could improve control of the COVID-19 pandemic. We compare monovalent and bivalent mRNA vaccines encoding B.1.351 (Beta) and/or...
4.
Lenart K, Hellgren F, Ols S, Yan X, Cagigi A, Cerveira R, et al.
Mol Ther Methods Clin Dev
. 2022 Oct;
27:309-323.
PMID: 36217434
A third vaccine dose is often required to achieve potent, long-lasting immune responses. We investigated the effect of three 8-μg doses of CVnCoV, CureVac's severe acute respiratory syndrome coronavirus 2...
5.
Roth N, Schon J, Hoffmann D, Thran M, Thess A, Mueller S, et al.
Vaccines (Basel)
. 2022 Aug;
10(8).
PMID: 36016139
More than two years after the emergence of SARS-CoV-2, 33 COVID-19 vaccines, based on different platforms, have been approved in 197 countries. Novel variants that are less efficiently neutralised by...
6.
Gebre M, Rauch S, Roth N, Gergen J, Yu J, Liu X, et al.
NPJ Vaccines
. 2022 Aug;
7(1):88.
PMID: 35915094
mRNA vaccines can be developed and produced quickly, making them prime candidates for immediate outbreak responses. Furthermore, clinical trials have demonstrated rapid protection following mRNA vaccination. Thus, we sought to...
7.
Gebre M, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado N, et al.
Nature
. 2021 Nov;
601(7893):410-414.
PMID: 34794169
The CVnCoV (CureVac) mRNA vaccine for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was recently evaluated in a phase 2b/3 efficacy trial in humans. CV2CoV is a second-generation mRNA vaccine containing...
8.
Gebre M, Rauch S, Roth N, Gergen J, Yu J, Liu X, et al.
bioRxiv
. 2021 Nov;
PMID: 34751269
Importance: mRNA vaccines can be developed and produced in record time. Here we demonstrate induction of rapid antibody responses by mRNA vaccines encoding two different viral antigens by day 5...
9.
Kremsner P, Mann P, Kroidl A, Leroux-Roels I, Schindler C, Gabor J, et al.
Wien Klin Wochenschr
. 2021 Aug;
133(17-18):931-941.
PMID: 34378087
Background: We used the RNActive® technology platform (CureVac N.V., Tübingen, Germany) to prepare CVnCoV, a COVID-19 vaccine containing sequence-optimized mRNA coding for a stabilized form of SARS-CoV‑2 spike (S) protein...
10.
Hoffmann D, Corleis B, Rauch S, Roth N, Muhe J, Halwe N, et al.
Nat Commun
. 2021 Jul;
12(1):4048.
PMID: 34193869
The ongoing SARS-CoV-2 pandemic necessitates the fast development of vaccines. Recently, viral mutants termed variants of concern (VOC) which may escape host immunity have emerged. The efficacy of spike encoding...